Perspective Therapeutics (NYSE:CATX) Shares Down 3.6% – What’s Next?

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) were down 3.6% on Wednesday . The stock traded as low as $12.70 and last traded at $12.70. Approximately 80,311 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 660,066 shares. The stock had previously closed at $13.17.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on CATX shares. Royal Bank of Canada decreased their price target on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a research note on Friday, August 16th. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Truist Financial began coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They set a “buy” rating and a $21.00 target price on the stock. Bank of America started coverage on shares of Perspective Therapeutics in a research note on Thursday, July 25th. They issued a “buy” rating and a $24.00 price objective for the company. Finally, Oppenheimer cut their target price on shares of Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Perspective Therapeutics has an average rating of “Buy” and an average target price of $20.71.

Perspective Therapeutics Price Performance

The business’s 50 day moving average price is $13.83.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.04. The company had revenue of $0.53 million for the quarter. Equities research analysts expect that Perspective Therapeutics, Inc. will post -0.86 earnings per share for the current year.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds have recently modified their holdings of CATX. RIA Advisory Group LLC grew its stake in Perspective Therapeutics by 1,313.4% in the 1st quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after purchasing an additional 99,293 shares during the period. Bleakley Financial Group LLC bought a new position in Perspective Therapeutics during the first quarter valued at about $40,000. Vanguard Group Inc. grew its position in Perspective Therapeutics by 34.6% during the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after buying an additional 4,566,356 shares during the period. Affinity Asset Advisors LLC bought a new position in Perspective Therapeutics during the first quarter valued at about $6,069,000. Finally, Janus Henderson Group PLC bought a new position in Perspective Therapeutics during the first quarter valued at about $15,511,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.